Abstract library

56 results for "Ueno".
#2239 pNET G3 Tumor Stabilization Achieved by an Individualized Molecular Therapy Based on Tumor Genome Sequencing Results
Introduction: High-grade pancreatic neuroendocrine neoplasms (pNENs) constitute a heterogeneous group of malignant neoplasms, encompassing neuroendocrine tumors (NET) G3 and carcinomas (NEC). Due to poor data on NET G3 tumors no standard therapy in metastatic disease could be established so far. Tumor genome sequencing might help to better profile NET G3 tumors and could provide novel opportunities for individualized and thereby successful patient specific treatments.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Martina Steurer
#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#2145 Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience
Introduction: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms associated with paraneoplastic syndromes. Venous thromboembolism (VTE) is a frequent complication in neoplastic patients and it is associated with increased morbidity and mortality. To date, there have been no specific studies in NEN, except for glucagon-secreting tumors
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Federica Alessandra Cavalcoli
#839 Complete Mesenterial Venous Obstruction – A Clinical Syndrome Unique to Neuroendocrine Neoplasms of the Small Bowel
Introduction: Neuroendocrine neoplasms of the small bowel are mostly advanced or metastasized at diagnosis. Metastases typically occur in the mesenteric root and liver.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Prof. Dieter Hörsch
Keywords: NET
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#722 Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study
Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Dalvinder Mandair
#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin
Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Wenzel M Hackeng
#562 Expression of Chromosome 18 Related Tumor Suppressor Proteins in Ileal Neuroendocrine Tumors
Introduction: The genetic alterations in ileal neuroendocrine tumors (iNETs) are poorly
characterized. The most frequent chromosomal aberration is the loss of one
chromosome 18 in iNETs, however, the relevance of this alteration is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Tobias Henopp
#564 Genetic Alterations in Glucagon Cell Adenomatosis
Introduction: Glucagon cell adenomatosis (GCA) was recently recognized by us as a multifocal neoplastic disease of the endocrine pancreas unrelated to MEN-1. Multiple micro- and a few macrotumors are found on the background of a hyperplasia of glucagon cells. The disease may cause unspecific abdominal symptoms and only rarely a glucagonoma syndrome. Recently a mutation in the glucagon receptor (GCGR) gene was described in one GCA
patient.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Tobias Henopp
Keywords: glucagon
#565 Proliferative Activity is Not Associated with Tumor Aggressiveness in Ileal Neuroendocrine Tumors
Introduction: The accuracy of the new WHO grading system for neuroendocrine neoplasms has not yet been validated for ileal neuroendocrine tumors (iNETs).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Tobias Henopp